Treating respiratory infections in the era of cost control.
The treatment of lower respiratory tract infections will undoubtedly be affected by cost-control measures. Probably the most important change in the diagnosis and treatment of bronchitis and pneumonia will be a more empiric approach. A basic knowledge of likely pathogens, plus the clinical judgment to provide treatment modifications for patients susceptible to unusual pathogens, will usually assure a successful outcome.
D000328:Adult; D000368:Aged; D000375:Aging; D000900:Anti-Bacterial Agents; D001991:Bronchitis / Q000175:diagnosis / Q000188:drug therapy; D003363:Cost Control / Q000639:trends; D004352:Drug Resistance, Microbial; D006760:Hospitalization; D006801:Humans; D007902:Length of Stay; D008875:Middle Aged; D011014:Pneumonia / Q000175:diagnosis / Q000188:drug therapy; D012137:Respiratory System / Q000503:physiopathology; D012141:Respiratory Tract Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D012907:Smoking; D014780:Viruses
D000900:Anti-Bacterial Agents